Searchable abstracts of presentations at key conferences in endocrinology

ea0029p646 | Diabetes | ICEECE2012

Microvascular complications in type 1 diabetes mellitus: prevalence and associated risk factors in DIACAM 1 study

Lopez J , Aguirre M , Lopez L , Roa C , Gomez I , Aranda S , Lamas C , Vicente A , Sastre J

Background and aims: DIACAM1 study was designed to investigate the clinical characteristics of a representative group of type 1 diabetic (T1D) population in Castilla-La Mancha (Spain). The aim of this report is to describe the prevalence of microvascular complications and the factors associated with such complications.Materials and methods: This is an observational, cross-sectional, prospective and multicentre study of 1465 patients who received assistan...

ea0037oc7.5 | Neuroendocrinology and pituitary-basic | ECE2015

Not so giants: mice lacking both somatostatin and cortistatin have high GH levels, but show no changes in growth rate or IGF-I levels

Luque Raul M , Gahete Manuel D , Pedraza-Arevalo Sergio , Pozo-Salas Ana I , L-Lopez Fernando , de Lecea Luis , Cordoba-Chacon Jose , Castano Justo P

Somatostatin (SST) and cortistatin (CORT) are two highly related neuropeptides involved in the regulation of several endocrine secretions. In particular, SST and CORT are two primary negative regulators of GH secretion. Consequently, SST or CORT knockout (KO) mice exhibit elevated GH levels; however, this does not lead to increased IGF-I levels or somatic growth, which has been suggested that could be due to a compensatory mechanism between both peptides. In order to test this...

ea0011p893 | Thyroid | ECE2006

Cytostatic effect of plitidepsin (AplidinTM) in human undifferentiated (anaplastic) thyroid carcinoma

Bravo Susana , garcia-renduelles Maria , Seoane Rafael , Dosil Vanesa , Cameselle Jose , Lopez-Lázaro Luis , Zalvide Juan , Barreiro Franci , Pombo Celia , Alvarez Clara

Undifferentiated thyroid carcinoma is a highly aggressive human cancer with poor prognosis. A strong association has been observed between undifferentiated thyroid carcinoma and TP53 mutations. Plitidepsin (AplidinTM) a novel anticancer compound from a sea tunicate, has been reported to induce apoptosis independently of TP53 status. We investigated the actions of plitidepsin in human thyroid cancer cells. initiallyexperiments using primary cultured cells from a d...

ea0056oc4.1 | Novel insights into prediabetes and type 2 diabetes | ECE2018

Dietary intervention modulates the expression of the splicing machinery in patients at high-risk of type 2 diabetes development: clinical implications

del Rio-Moreno Mercedes , Alors-Perez Emilia , Camargo Antonio , Delgado-Lista Javier , Lopez-Canovas Juan L. , Lopez-Miranda Jose , Luque Raul M. , Gahete Manuel D. , Castano Justo P.

Development of type-2 diabetes (T2D) is critically affected by the loss of phenotypic flexibility. There is emerging evidence suggesting that, under adverse metabolic conditions, alternative mRNA splicing is markedly dysregulated at different levels. For this reason, we hypothesized that such dysregulation could contribute to loss of phenotypic flexibility. Consequently, we aimed to explore whether changes in the splicing machinery in peripheral blood mononuclear cells (PBMCs)...

ea0056gp157 | Obesity | ECE2018

Obesity is associated with a dysregulation in the splicing machinery components at the hepatic level: influence of metformin

L-Lopez Fernando , Alors-Perez Emilia , del Rio-Moreno Mercedes , Sarmento-Cabral Andre , Castano Justo P , Luque Raul M , Gahete Manuel D

Obesity, a multifactorial chronic endocrine-metabolic disease, represents one of the most serious and complex global health threats, as it is commonly associated with multiple and severe comorbidities (e.g. diabetes type-2). Indeed, as a source of severe metabolic-dysregulation, obesity alters physiological, homeostatic gene expression patters in multiple metabolic-tissues, including the central metabolic hub, i.e. the liver. However, the precise molecular mechanisms underlyin...

ea0063gp171 | Obesity (1) | ECE2019

A new generation somatostatin-dopamine chimeric analogue exerts potent antitumoral actions on primary pituitary neuroendocrine tumor cells

Alors-Perez Emilia , Vazquez-Borrego Mari C , L-Lopez Fernando , Galvez-Moreno Maria A , Fuentes-Fayos Antonio C , Venegas-Moreno Eva , Herrera-Martinez Aura D , Blanco-Acevedo Cristobal , Solivera Juan , Landsman Tanya , D Gahete Manuel , Soto-Moreno Alfonso , Culler Michael D , Castano Justo P , Luque Raul M

Pituitary neuroendocrine tumors (PitNETs) constitute approximately 15% of all intracranial tumors and comprise a varied type of neoplasms that, despite being rarely metastatic, can cause severe comorbidities and increased mortality related to the mass effects and hormonal hypersecretion. The high expression levels of somatostatin and dopamine receptors in these tumors has led to the use of somatostatin analogues (SSAs) and dopamine agonists (DAs) as pharmacological treatments....

ea0063p651 | Interdisciplinary Endocrinology 1 | ECE2019

Biguanides exert antitumoral actions in pituitary tumor cells through AMPK-dependent and -independent mechanisms

Herrera-Martinez Aura D , Vazquez-Borrego Mari C , Fuentes-Fayos Antonio C , L-Lopez Fernando , Ibanez-Costa Alejandro , Moreno Paloma Moreno , Alhambra-Exposito Maria R , Barrera-Martin Ana , Blanco-Acevedo Cristobal , Dios Elena , Venegas-Moreno Eva , Solivera Juan , Gahete Manuel D , Soto-Moreno Alfonso , Galvez-Moreno Maria A , Castano Justo P , Luque Raul M

Background: Pituitary adenomas represent a commonly underestimated pathology in terms of incidence and associated morbimortality. Additionally, some patients poorly respond or develop resistance to current medical treatments [i.e. somatostatin analogues (SSAs) and dopamine agonists]. In this context, it is necessary to develop novel and/or optimize currently available medical therapies. Biguanides (metformin, buformin and phenformin) are antidiabetic drugs that have been descr...